Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT02942524 Completed - Malignant Neoplasm Clinical Trials

Checklist Tool in Engaging Patients in the Discharge Planning Process

TEPID
Start date: April 2016
Phase: N/A
Study type: Interventional

This clinical trial studies how well a checklist tool works in engaging patients in the discharge planning process. Engaging patients in the discharge process may increase participation in the discharge process and improve discharge outcomes, understanding of care after hospitalization, and decrease complications.

NCT ID: NCT02942095 Completed - Solid Tumors Clinical Trials

Study of Ixazomib and Erlotinib in Solid Tumors

Start date: March 6, 2017
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is to find the highest tolerable dose of the combination of ixazomib and erlotinib that can be given to patients with advanced solid tumors. The safety of these drugs will also be studied. This is an investigational study. Erlotinib is FDA approved and commercially available to treat non-small cell lung cancer, but its use in advanced solid cancer is considered investigational. Ixazomib is FDA approved. The study doctor can explain how the study drugs are designed to work. Up to 36 patients will take part in this study. All will be enrolled at MD Anderson.

NCT ID: NCT02940223 Terminated - Fatigue Clinical Trials

Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer

Start date: March 16, 2017
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well ethyl icosapentate and physical activity work in treating fatigue in patients with cancer that has spread from where it started to other places in the body. Ethyl icosapentate and physical activity may provide more robust and clinically effective improvement of cancer related fatigue, which may facilitate patients continuing cancer therapy since it would be tolerated and effective in controlling disease.

NCT ID: NCT02940041 Terminated - Leiomyoma Clinical Trials

Concordance Between Sonography Amd MRI for Presurgical Diagnosis of Uterine Mesenchymal Malignant Tumors

CERTUM
Start date: September 2016
Phase:
Study type: Observational

Determine the concordance between gynaecological sonography and pelvic MRI for the pre-surgical diagnosis of uterine malignant tumors.

NCT ID: NCT02937272 Active, not recruiting - Solid Tumor Clinical Trials

A Study of LY3200882 in Participants With Solid Tumors

Start date: November 21, 2016
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.

NCT ID: NCT02937246 Enrolling by invitation - Malignant Tumor Clinical Trials

Efficacy of Partial Covered Double Bare Metal Stent Compared to Uncovered Double Bare Metal Stent in Malignant Biliary Obstruction

Start date: May 31, 2016
Phase: N/A
Study type: Interventional

Previous studies indicated that covered stents are less likely to become occluded in comparison to bare stents. While the probability of occlusions caused by tumor in-growth is less in covered stents, they are more likely to spontaneously migrate to a position that is distal to the original deployment site. However, newer covered stents with improved designs, such as the partially covered double bare metallic stent used for this study, include features to mitigate the migration issue. The purpose of this study is to confirm whether the difference in patency rate between regular covered stents and bare stents, which has already been well established by existing studies, is also reproducible when double covered stents are compared against double bare stents.

NCT ID: NCT02937116 Completed - Cancer, Solid Tumor Clinical Trials

First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors

Start date: October 19, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability and efficacy of IBI308 monotherapy or in combination with chemotherapy in patients with certain types of advanced solid tumors. Another purpose is to determine the pharmacokinetics, pharmacodynamics and immunogenicity of IBI308.

NCT ID: NCT02934568 Recruiting - Clinical trials for Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies

Ribociclib (LEE011) Rollover Study for Continued Access

Start date: December 15, 2016
Phase: Phase 2
Study type: Interventional

This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis-sponsored ribociclib (LEE011) study that has reached its primary objective(s) or has been halted for other reasons.

NCT ID: NCT02933333 Recruiting - Lymphoma Clinical Trials

G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor

Start date: September 27, 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to explore the effect of G-CSF combination with GM-CSF on prevention and treatment of infection in children with malignant tumor.

NCT ID: NCT02932280 Active, not recruiting - Lymphoma Clinical Trials

Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment

Start date: October 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test the safety of neratinib at different dose levels and to find out what effects, good and bad, it has on the patients and the cancer.